Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 Medications prescribed at study start (N = 64) and study end (N = 63)

From: Early identification and preventive care for elevated cardiovascular disease risk within a remote Australian Aboriginal primary health care service

Drug class Baseline N (%) Study end N (%) P*
Anti-platelet 3 (4.7%) 43 (68.3%) < 0.001
Lipid lowering 4 (6.3%) 41 (65.1%) < 0.001
ACEi/ARB 16 (25%) 40 (63.5%) < 0.001
Oral hypoglycaemic 11 (17.2%) 21 (33.3%) 0.04
Beta blocker 3 (4.7%) 8 (12.7%) 0.09
Nitrate 2 (3.1%) 3 (4.8%) 0.49
Thiazide diuretic 0 2 (3.2%) 0.24
Calcium channel blocker 1 (1.6%) 1 (1.6%) 0.75
  1. Notes: ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker.
  2. * Chi Square test for change in proportion of participants prescribed each class of medication.
  3. † There was one death in the period following the AHC.
  4. Baseline = 3 years prior to date of AHC participation.
  5. Study end = 3 years following date of AHC participation.